Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1554 Trials   75234 News 


«12...148149150151152153154155156157158...859860»
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Harlequin syndrome. (Pubmed Central) -  Jul 17, 2023   
    He was started on erenumab for migraine prophylaxis and was given sumatriptan for abortive therapy following which his headaches improved. The patient was diagnosed with idiopathic left Horner's syndrome and his migraines with autonomic dysfunction would present with unilateral flushing opposite to the site of Horner's presenting as Harlequin syndrome [1, 2].
  • ||||||||||  Review, Journal, Gene therapy:  Clinical applications of gene therapy for rare diseases: A review. (Pubmed Central) -  Jul 17, 2023   
    An initial comparison of the effectiveness of AAV and oligonucleotide therapies in SMA is possible with Zolgensma, an AAV serotype 9 vector, and Spinraza. Through these examples of marketed gene therapies and gene cell therapies, we will discuss the expanding applications of such novel technologies to previously intractable rare diseases.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Trial primary completion date:  Intrauterine Infusion of GCSF and Reproductive Outcomes in Infertile Women with History of RIF (clinicaltrials.gov) -  Jul 17, 2023   
    P=N/A,  N=100, Recruiting, 
    Through these examples of marketed gene therapies and gene cell therapies, we will discuss the expanding applications of such novel technologies to previously intractable rare diseases. Trial primary completion date: Mar 2023 --> Jul 2023
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Enrollment change, Trial withdrawal:  Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC (clinicaltrials.gov) -  Jul 17, 2023   
    P2,  N=0, Withdrawn, 
    Trial primary completion date: Mar 2023 --> Jul 2023 N=25 --> 0 | Recruiting --> Withdrawn
  • ||||||||||  anbenitamab (KN026) / Alphamab
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer (clinicaltrials.gov) -  Jul 17, 2023   
    P2,  N=4, Terminated, 
    N=25 --> 0 | Recruiting --> Withdrawn N=36 --> 4 | Trial completion date: Dec 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Mar 2023; Difficulty in completing enrollment within the planned time
  • ||||||||||  zotatifin (eFT226) / eFFECTOR Therap
    Enrollment change, Trial completion date, Trial primary completion date:  Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (clinicaltrials.gov) -  Jul 17, 2023   
    P1/2,  N=30, Recruiting, 
    N=36 --> 4 | Trial completion date: Dec 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Aug 2023 --> Mar 2023; Difficulty in completing enrollment within the planned time N=228 --> 30 | Trial completion date: Sep 2023 --> Mar 2025 | Trial primary completion date: Jul 2023 --> Dec 2024
  • ||||||||||  Retrospective data, Review, Journal:  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) -  Jul 16, 2023   
    Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
  • ||||||||||  hydroxyurea / Generic mfg.
    Enrollment open, Enrollment change:  ACHiEvE-SCD: Hydroxyurea and EPO in Sickle Cell Disease (clinicaltrials.gov) -  Jul 14, 2023   
    P1/2,  N=15, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=25 --> 15
  • ||||||||||  Imlygic (talimogene laherparepvec) / Amgen
    Review, Journal, Oncolytic virus, Tumor cell:  Development and application of oncolytic viruses as the nemesis of tumor cells. (Pubmed Central) -  Jul 13, 2023   
    In recent years, oncolytic virus therapy has shown increasingly promising application prospects and has become a major research focus in the field of cancer treatment. This article reviews the development, classification, and research progress of oncolytic viruses, as well as their mechanisms of action, therapeutic methods, and routes of administration.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial primary completion date:  Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) -  Jul 12, 2023   
    P2,  N=30, Recruiting, 
    Our results show suboptimal persistence to medications that varied across different databases and treatment switching was relatively rare. Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Mektovi (binimetinib) / Pfizer
    Trial initiation date:  Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (clinicaltrials.gov) -  Jul 12, 2023   
    P2,  N=199, Not yet recruiting, 
    Trial primary completion date: Sep 2023 --> Dec 2023 Initiation date: Dec 2022 --> Sep 2023
  • ||||||||||  Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date:  Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma (clinicaltrials.gov) -  Jul 12, 2023   
    P2,  N=14, Active, not recruiting, 
    Initiation date: Dec 2022 --> Sep 2023 Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
  • ||||||||||  Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
    Trial completion date, Trial primary completion date:  A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (clinicaltrials.gov) -  Jul 12, 2023   
    P2/3,  N=120, Recruiting, 
    Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 Trial completion date: Nov 2029 --> Jul 2031 | Trial primary completion date: Dec 2023 --> May 2031
  • ||||||||||  mirdametinib (PD-0325901) / SpringWorks Therap, Ibrance (palbociclib) / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy:  PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors (clinicaltrials.gov) -  Jul 12, 2023   
    P1/2,  N=139, Active, not recruiting, 
    Trial completion date: Nov 2029 --> Jul 2031 | Trial primary completion date: Dec 2023 --> May 2031 Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Aug 2023
  • ||||||||||  Thalagen (autologous CD34+ cells transduced with TNS9.3.55) - San Rocco Therap, Memorial Sloan / Kettering Cancer Center
    Trial completion date, Trial primary completion date, Viral vector:   (clinicaltrials.gov) -  Jul 12, 2023   
    P1,  N=10, Active, not recruiting, 
    Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Aug 2023 Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  cyclophosphamide / Generic mfg., clofarabine / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Post-transplantation:  Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML (clinicaltrials.gov) -  Jul 12, 2023   
    P2,  N=2, Terminated, 
    N=72 --> 120 N=20 --> 2 | Trial completion date: Jun 2026 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Aug 2022; terminated due to low accrual
  • ||||||||||  Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer
    Enrollment closed:  REGONIVOCTx: Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy (clinicaltrials.gov) -  Jul 12, 2023   
    P1/2,  N=30, Active, not recruiting, 
    N=20 --> 2 | Trial completion date: Jun 2026 --> Nov 2022 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Aug 2022; terminated due to low accrual Recruiting --> Active, not recruiting
  • ||||||||||  Lumakras (sotorasib) / Amgen, Tarlox (tarloxotinib bromide) / Pathos
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Tarlox and Sotorasib in Patients With KRAS G12C Mutations (clinicaltrials.gov) -  Jul 12, 2023   
    P1/2,  N=5, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=30 --> 5 | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2023 --> Jul 2023
  • ||||||||||  acapatamab (AMG 160) / Amgen, BeiGene
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC (clinicaltrials.gov) -  Jul 12, 2023   
    P1,  N=212, Completed, 
    Recruiting --> Active, not recruiting | N=240 --> 137 Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jul 2023 | Trial primary completion date: May 2025 --> Jul 2023
  • ||||||||||  Repatha (evolocumab) / Amgen, Astellas
    Trial completion, Enrollment change:  Effect of Evolocumab on Vascular Function (clinicaltrials.gov) -  Jul 12, 2023   
    P4,  N=105, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2025 --> Jul 2023 | Trial primary completion date: May 2025 --> Jul 2023 Recruiting --> Completed | N=65 --> 105